Laboratory-Based Markers as Predictors of Brain Infarction During Carotid Stenting: a Prospective Study
Abstrakt
Aim: New ischemic lesions in the brain can be detected in approximately 50% of patients undergoing carotid artery stenting (CAS). We wished to discover the laboratory-based predictors of new infarctions in the brain after CAS.
Methods: All consecutive patients with internal carotid artery stenosis of >= 70% with indication for CAS were enrolled in a prospective study for 16 months. All patients used dual antiplatelet therapy for >= 7 days before CAS.
Neurologic examination and magnetic resonance imaging (MRI) of the brain were undertaken before and at 24 h after CAS. Samples of venous blood were collected at <24 h before CAS for the evaluation of hematology, reticulocytes, coagulation markers (PT, APTT, Fbg, Clauss), vWF antigen, PAI-1 activity, PAI-1 polymorphism 4G/5G, and the multiplate (aspirin and clopidogrel) resistance test.
Blood samples for the assessment of anti-Xa activity were collected during CAS. Differences in the values of laboratory markers between patients with and without new ischemic lesions of the brain on control MRI were evaluated.
Results: The cohort comprised 81 patients (53 males; mean age, 67.3 +/- 7.2 years). New ischemic infarctions in the brain on control MRI were found in 46 (56.8%) patients.
Three of seven patients with resistance to aspirin or clopidogrel had a new ischemic infarction in the brain. No significant differences for particular markers were found between patients with and without an ischemic lesion in the brain.
Conclusion: A high risk of a new ischemic infarction in the brain was detected in patients undergoing CAS, but a laboratory-based predictor of such an infarction could not be identified.